Summary
Amgen Inc. (AMGN) filed an 8-K on July 29, 2014, primarily to report its second-quarter 2014 financial results and announce a significant restructuring plan. The company reported its unaudited results of operations for the three and six months ended June 30, 2014, and its financial position as of June 30, 2014, providing adjusted earnings per share, free cash flow, and other non-GAAP financial measures. This filing also detailed a strategic restructuring initiative approved by the Board of Directors to optimize operations and cost structure in light of pipeline developments and the expansion into biosimilars. The restructuring plan involves a substantial workforce reduction, impacting approximately 12% to 15% of its then-current staff (2,400 to 2,900 positions), and the closure or disposal of several facilities in Washington and Colorado. These actions are expected to result in significant pre-tax restructuring charges, estimated to be between $775 million and $950 million, incurred primarily in 2014 and 2015. Management believes these measures are necessary to align the company's capabilities with its strategic objectives and improve its financial efficiency.
Key Highlights
- 1Amgen announced its unaudited financial results for the second quarter and first half of 2014, including key non-GAAP metrics.
- 2The company is undertaking a major restructuring plan affecting approximately 12-15% of its global workforce (2,400-2,900 employees).
- 3Facilities in Seattle and Bothell, Washington, and Boulder and Longmont, Colorado, are slated for closure or disposal.
- 4Total pre-tax restructuring charges are estimated to range between $775 million and $950 million.
- 5These charges will be incurred primarily in 2014 and 2015.
- 6Approximately 40% of the cumulative restructuring charges are expected to result in cash outlays.
- 7The restructuring aims to align capabilities with Amgen's strategy, including pipeline developments and biosimilar expansion, while improving cost structure.